Výpis publikací

SZCZEPANIK, Pawel Marcin; Andrey MIKHAYLOV; Ondřej HYLSE; Roman KUČERA; Petra DAĎOVÁ; Marek NEČAS; Lukáš KUBALA; Kamil PARUCH a Jakub ŠVENDA. Convergent Assembly of the Tricyclic Labdane Core Enables Synthesis of Diverse Forskolin-like Molecules. Angewandte Chemie International Edition. Wiley, 2023, roč. 62, č. 1, s. 1-7. ISSN 1433-7851. Dostupné z: https://doi.org/10.1002/anie.202213183.

HYLSE, Ondřej; Lukáš MAIER; Roman KUČERA; Tomáš PEREČKO; Aneta SVOBODOVÁ; Lukáš KUBALA; Kamil PARUCH a Jakub ŠVENDA. A Concise Synthesis of Forskolin. Angewandte Chemie International Edition. Německo: Verlag Chemie, 2017, roč. 2017, č. 56, s. 12586-12589. ISSN 1433-7851. Dostupné z: https://doi.org/10.1002/anie.201706809.

PACULOVÁ, Hana; Juraj KRAMARA; Šárka ŠIMEČKOVÁ; Radek FEDR; Karel SOUČEK; Ondřej HYLSE; Kamil PARUCH; Marek SVOBODA; Martin MISTRÍK a Jiří KOHOUTEK. BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors. Tumor Biology. Springer Netherlands, 2017, roč. 2017, October, s. 1-11. ISSN 1010-4283. Dostupné z: https://doi.org/10.1177/1010428317727479.

MAIER, Lukáš; PrashantKumar KHIRSARIYA; Ondřej HYLSE; Santosh Kumar ADLA; Lenka ČERNOVÁ; Michal POLJAK; Soňa KRAJČOVIČOVÁ; Erik WEIS; Stanislav DRÁPELA; Karel SOUČEK a Kamil PARUCH. Diastereoselective Flexible Synthesis of Carbocyclic C Nucleosides. The Journal of Organic Chemistry. WASHINGTON, DC USA: American Chemical Society, 2017, roč. 82, č. 7, s. 3382-3402. ISSN 0022-3263. Dostupné z: https://doi.org/10.1021/acs.joc.6b02594.

SAMADDER, Pounami; Tereza SUCHÁNKOVÁ; Ondřej HYLSE; PrashantKumar KHIRSARIYA; Fedor NIKULENKOV; Stanislav DRÁPELA; Nicol STRAKOVÁ; Petr VAŇHARA; Kateřina VAŠÍČKOVÁ; Hana KOLÁŘOVÁ; Lucia BINÓ; Miroslava BITTOVÁ; Petra OVESNÁ; Peter KOLLÁR; Radek FEDR; Milan EŠNER; Josef JAROŠ; Aleš HAMPL; Lumír KREJČÍ; Kamil PARUCH a Karel SOUČEK. Synthesis and Profiling of a Novel Potent Selective Inhibitor of CHK1 Kinase Possessing Unusual N-trifluoromethylpyrazole Pharmacophore Resistant to Metabolic N-dealkylation. Molecular Cancer Therapeutics. Philadelphia: American Association for Cancer Research, 2017, roč. 16, č. 9, s. 1831-1842. ISSN 1535-7163. Dostupné z: https://doi.org/10.1158/1535-7163.MCT-17-0018.

BITTOVÁ, Miroslava; Hana KOLÁŘOVÁ; Ondřej HYLSE; PrashantKumar KHIRSARIYA a Kamil PARUCH. Development and validation of a highly sensitive LC-MS method for determination of checkpoint kinase 1 inhibitors in mouse plasma. In Vítězslav Maier. Advances in chromatography and electrophoresis & Chiranal 2016. Olomouc: Palacký University, Olomouc, 2016, s. 79-80. ISBN 978-80-244-4961-6.

ZEMANOVÁ, Jana; Ondřej HYLSE; Jana ČOLLÁKOVÁ; Petr VESELÝ; Alexandra OLTOVÁ; Kamil PARUCH a Martin TRBUŠEK. Checkpoint kinase 1 inhibition potentiates apoptosis and inflicts mitotic failure in CLL-derived MEC-1 cell line. In Haematologica (2016); 101(s1): 425. (21st Congress of the EHA). 2016.

ZEMANOVÁ, Jana; Ondřej HYLSE; Jana COLLAKOVA; Pavel VESELY; Alexandra OLTOVÁ; Marek BORSKÝ; Kristína ZÁPRAŽNÁ; Marie KAŠPÁRKOVÁ; Pavlína JANOVSKÁ; Jan VERNER; Jiri KOHOUTEK; Marta DZIMKOVA; Vítězslav BRYJA; Zuzana JAŠKOVÁ; Yvona BRYCHTOVÁ; Kamil PARUCH a Martin TRBUŠEK. Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells. Oncotarget. Albany: Impact Journals, 2016, roč. 7, č. 38, s. 62091-62106. ISSN 1949-2553. Dostupné z: https://doi.org/10.18632/oncotarget.11388.

KUČERA, Roman; Ondřej HYLSE; Michal BABIAK a Jakub ŠVENDA. Facile rearrangements of a vinylogous alpha-hydroxy-beta-dicarbonyl substrate involving an apparent oxirane C-C bond scission. Tetrahedron Letters. OXFORD: Pergamon Press, 2015, roč. 56, č. 45, s. 6171-6173. ISSN 0040-4039. Dostupné z: https://doi.org/10.1016/j.tetlet.2015.09.015.

ZEMANOVÁ, Jana; Kamil PARUCH; Lumír KREJČÍ; Karel SOUČEK; Ondřej HYLSE; Miroslav BOUDNÝ; Marek BORSKÝ; Jitka OSIČKOVÁ; PrashantKumar KHIRSARIYA; Ludmila ŠEBEJOVÁ; Veronika NAVRKALOVÁ; Jitka MALČÍKOVÁ; Eva DIVÍŠKOVÁ; Yvona BRYCHTOVÁ; Jiří MAYER a Martin TRBUŠEK. Chronic lymphocytic leukemia cells are highly susceptible to direct inhibition of checkpoint kinase. In 20th Congress of the European Hematology Association in Haematologica. 2015.

SAMADDER, Pounami. Exploring synthetic lethal interaction between Checkpoint Kinase 1(CHK1) and DNA replication stress. In HYLSE, Ondřej; Fedor NIKULENKOV; Tereza SUCHÁNKOVÁ; Karel SOUČEK; Kamil PARUCH a Lumír KREJČÍ. Cell Proliferation and Genome Integrity International symposium. 2014.

ZEMANOVÁ, Jana; Ludmila ŠEBEJOVÁ; Ondřej HYLSE; Kamil PARUCH; Šárka POSPÍŠILOVÁ a Martin TRBUŠEK. Is checkpoint kinase 1 a suitable molecular target for combination with cancer chemotherapeutics? In XXI. Biologické dny, Brno. 2014.

ZEMANOVÁ, Jana; Ludmila ŠEBEJOVÁ; Ondřej HYLSE; Kamil PARUCH; Šárka POSPÍŠILOVÁ a Martin TRBUŠEK. Is checkpoint kinase 1 a suitable molecular target for sensitization of TP53-mutated leukemia and lymphoma cells to chemotherapy? In 16th International p53 workshop, Švédsko. 2014.

MAIER, Lukáš; Ondřej HYLSE; Marek NEČAS; Martin TRBUŠEK; Mari YTRE-ARNE; Bjorn DALHUS; Magnar BJORAS a Kamil PARUCH. New carbocyclic nucleosides: synthesis of carbocyclic pseudoisocytidine and its analogs. Tetrahedron Letters. 2014, roč. 55, č. 27, s. 3713-3716. ISSN 0040-4039. Dostupné z: https://doi.org/10.1016/j.tetlet.2014.05.030.

ZEMANOVÁ, Jana; Ludmila ŠEBEJOVÁ; Kamil PARUCH; Ondřej HYLSE; Šárka POSPÍŠILOVÁ; Jiří MAYER a Martin TRBUŠEK. Synthetic lethality in p53 mutated B-cell mylignancies: Chk-1 inhibition and DNA-PK inhibition effect in cell lines and primary CLL cells. In 18th Congress of the European Hematology Association in Haematologica, the hematology journal, Stockholm, Švédsko. 2013.

ZEMANOVÁ, Jana; Ludmila ŠEBEJOVÁ; Ondřej HYLSE; Kamil PARUCH; Šárka POSPÍŠILOVÁ a Martin TRBUŠEK. Inhibice kinázy Chk1 senzitivuje buňky leukemií a lymfomů s mutacemi p53 na chemoterapeutika. In XXVI. Olomoucké hematologické dny s mezinárodní účastí, Olomouc. 2012.

ZEMANOVÁ, Jana; Ludmila ŠEBEJOVÁ; Ondřej HYLSE; Kamil PARUCH; Šárka PAVLOVÁ; Jiří MAYER; Šárka POSPÍŠILOVÁ a Martin TRBUŠEK. Inhibition of Chk1 kinase sensitizes leukemia and lymphoma cell lines with TP53 mutations to chemotherapy. In 54th ASH Annual Meeting and Exposition, Atlanta, USA in Blood. 2012.